274 related articles for article (PubMed ID: 37835806)
1. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
2. Theragnostic radionuclides: a clinical perspective.
Koziorowski J; Ballinger J
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):306-314. PubMed ID: 34881851
[TBL] [Abstract][Full Text] [Related]
3. The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years.
Balma M; Liberini V; Buschiazzo A; Racca M; Rizzo A; Nicolotti DG; Laudicella R; Quartuccio N; Longo M; Perlo G; Terreno E; Abgral R; William Huellner M; Papaleo A; Deandreis D
Curr Med Imaging; 2023; 19(8):817-831. PubMed ID: 36797602
[TBL] [Abstract][Full Text] [Related]
4. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
Morgan KA; Rudd SE; Noor A; Donnelly PS
Chem Rev; 2023 Oct; 123(20):12004-12035. PubMed ID: 37796539
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics.
Saldarriaga Vargas C; Bauwens M; Pooters INA; Pommé S; Peters SMB; Segbers M; Jentzen W; Vogg A; van Velden FHP; Meyer Viol SL; Gotthardt M; Mottaghy FM; Wildberger JE; Covens P; Wierts R
EJNMMI Phys; 2020 Nov; 7(1):69. PubMed ID: 33226485
[TBL] [Abstract][Full Text] [Related]
7. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract][Full Text] [Related]
8. PSMA theragnostics for metastatic castration resistant prostate cancer.
Song H; Guja KE; Iagaru A
Transl Oncol; 2022 Aug; 22():101438. PubMed ID: 35659674
[TBL] [Abstract][Full Text] [Related]
9. Theragnostics before we found its name.
Modoni S; Frangos S; Iakovou I; Boero M; Mansi L
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):299-305. PubMed ID: 35133096
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
11. Theragnostics in primary and secondary liver tumors: the need for a personalized approach.
Filippi L; Braat AJ
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):353-370. PubMed ID: 34881847
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
13. Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.
Cimini A; Ricci M; Chiaravalloti A; Filippi L; Schillaci O
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32481723
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging and Theragnostics of Thyroid Cancers.
Giovanella L; Deandreis D; Vrachimis A; Campenni A; Petranovic Ovcaricek P
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267580
[TBL] [Abstract][Full Text] [Related]
15. Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics.
Davis L; Smith AL; Aldridge MD; Foulkes J; Peet C; Wan S; Gains JE; Bomanji JB; Gaze MN
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33081161
[TBL] [Abstract][Full Text] [Related]
16. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent.
Capriotti G; Piccardo A; Giovannelli E; Signore A
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615024
[TBL] [Abstract][Full Text] [Related]
17. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory.
Srivastava SC
Semin Nucl Med; 2012 May; 42(3):151-63. PubMed ID: 22475424
[TBL] [Abstract][Full Text] [Related]
18. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
19. Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics.
Liberini V; Laudicella R; Balma M; Nicolotti DG; Buschiazzo A; Grimaldi S; Lorenzon L; Bianchi A; Peano S; Bartolotta TV; Farsad M; Baldari S; Burger IA; Huellner MW; Papaleo A; Deandreis D
Eur Radiol Exp; 2022 Jun; 6(1):27. PubMed ID: 35701671
[TBL] [Abstract][Full Text] [Related]
20. Economics of New Molecular Targeted Personalized Radiopharmaceuticals.
Cutler CS
Semin Nucl Med; 2019 Sep; 49(5):450-457. PubMed ID: 31470937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
